MYO vs CTKB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CTKB Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cytek Biosciences, Inc. Common Stock (CTKB) driven by superior Momentum & Technical, Options & Structure while MYO counters with relative strength in Growth & Margin. Fundamentally, MYO trades at N/M Forward P/E with -21.8% operating margin (+22.2% YoY revenue) versus CTKB at N/M Forward P/E and -22.5% operating margin (+1.8% YoY). In options structure, MYO sits in UNCLASSIFIED (81st %ile IV; Dealer Gamma Walls on Pro) against CTKB sits in CONSOLIDATION (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | MYO Revenue | CTKB Revenue | MYO Op. Margin | CTKB Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -430.8% | N/A | MYO |
| FY2019 | $0M | N/A | -281.3% | N/A | MYO |
| FY2020 | $10M | $90M | -138.5% | 14.7% | CTKB |
| FY2021 | $10M | $130M | -74.1% | 7.2% | CTKB |
| FY2022 | $20M | $160M | -68.6% | -1.1% | CTKB |
| FY2023 | $20M | $190M | -42.8% | -14.4% | CTKB |
| FY2024 | $30M | $200M | -19.1% | -10.2% | CTKB |
| FY2025 | $40M | $200M | -35.2% | -20.0% | CTKB |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MYO | CTKB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $33.7M | $826.6M | Larger Scale | CTKB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +22.2% | +1.8% | Higher Growth | MYO |
| Operating Margin (TTM) Profitability | -21.8% | -22.5% | Higher Margin | MYO |
| Net Profit Margin Profitability | -33.1% | -39.1% | Higher Margin | MYO |
| Return on Equity (ROE) Capital Efficiency | -173.5% | -23.2% | Higher ROE | CTKB |
| 52-Week Range Position Momentum | 16% ($1โ$2) | 91% ($3โ$6) | Stronger Trend | CTKB |
| Beta / 30D Volatility Risk Regime | 2.22ฮฒ ยท 107% Vol | 0.71ฮฒ ยท 67% Vol | Lower Realized Risk | CTKB |
| Unified Institutional Score Composite Signal | 40.1 / 100 (SELL) | 48.4 / 100 (HOLD) | Higher Composite | CTKB |